Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

Related Citations for PubMed (Select 22120678)


Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

Lu X, Xiao L, Wang L, Ruden DM.

Biochem Pharmacol. 2012 Apr 15;83(8):995-1004. doi: 10.1016/j.bcp.2011.11.011. Epub 2011 Nov 22. Review.


HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C.

Clin Cancer Res. 2011 Aug 1;17(15):5132-9. doi: 10.1158/1078-0432.CCR-11-0072. Epub 2011 May 10.


Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.

Meng Q, Chen X, Sun L, Zhao C, Sui G, Cai L.

Mol Cell Biochem. 2011 Feb;348(1-2):165-71. doi: 10.1007/s11010-010-0651-y. Epub 2010 Nov 17.


Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.

Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G.

Immunol Lett. 2006 Apr 15;104(1-2):146-55. Epub 2005 Dec 12.


Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.

Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.

Cancer Sci. 2012 Feb;103(2):342-9. doi: 10.1111/j.1349-7006.2011.02144.x. Epub 2011 Dec 13.


Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.

Scaltriti M, Serra V, Normant E, Guzman M, Rodriguez O, Lim AR, Slocum KL, West KA, Rodriguez V, Prudkin L, Jimenez J, Aura C, Baselga J.

Mol Cancer Ther. 2011 May;10(5):817-24. doi: 10.1158/1535-7163.MCT-10-0966. Epub 2011 Mar 7.


Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?

Arteaga CL.

Clin Cancer Res. 2011 Aug 1;17(15):4919-21. doi: 10.1158/1078-0432.CCR-11-1218. Epub 2011 Jun 13.


Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?

De Mattos-Arruda L, Cortes J.

Breast. 2012 Aug;21(4):604-7. doi: 10.1016/j.breast.2012.04.002. Epub 2012 May 5.


Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA.

J Clin Oncol. 2007 Dec 1;25(34):5410-7.


Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.

Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS.

Mol Cancer Ther. 2013 Apr;12(4):509-19. doi: 10.1158/1535-7163.MCT-12-0507. Epub 2013 Feb 8.


Hsp90: an emerging target for breast cancer therapy.

Beliakoff J, Whitesell L.

Anticancer Drugs. 2004 Aug;15(7):651-62. Review.


Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.

Leow CC, Chesebrough J, Coffman KT, Fazenbaker CA, Gooya J, Weng D, Coats S, Jackson D, Jallal B, Chang Y.

Mol Cancer Ther. 2009 Aug;8(8):2131-41. doi: 10.1158/1535-7163.MCT-08-1038. Epub 2009 Aug 11.


Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Stravopodis DJ, Margaritis LH, Voutsinas GE.

Curr Med Chem. 2007;14(29):3122-38. Review.


Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.

Oude Munnink TH, de Vries EG, Vedelaar SR, Timmer-Bosscha H, Schröder CP, Brouwers AH, Lub-de Hooge MN.

Mol Pharm. 2012 Nov 5;9(11):2995-3002. doi: 10.1021/mp3002182. Epub 2012 Oct 11.


Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.

Chen W, Wei F, Xu J, Wang Y, Chen L, Wang J, Guan X.

Int J Mol Med. 2011 Dec;28(6):985-91. doi: 10.3892/ijmm.2011.790. Epub 2011 Sep 1.


Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin.

Bagatell R, Beliakoff J, David CL, Marron MT, Whitesell L.

Int J Cancer. 2005 Jan 10;113(2):179-88.


Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.

Moser C, Lang SA, Stoeltzing O.

Anticancer Res. 2009 Jun;29(6):2031-42. Review.


Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.

Zajac M, Gomez G, Benitez J, Martínez-Delgado B.

BMC Med Genomics. 2010 Oct 4;3:44. doi: 10.1186/1755-8794-3-44.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk